Evidence map›Paper›PMID 36130084›Full record

ArticleBrain pathology (Zurich, Switzerland)2023

Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection.

Julián Henao-Restrepo, Carolina López-Murillo, Pablo Valderrama-Carmona, Natalia Orozco-Santa, Johana Gomez, Johanna Gutiérrez-Vargas, Renato Moraga, Jorge Toledo, Jessica Lisa Littau, Steffen Härtel and 6 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Inhibitory Roles ofThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Julián Henao-RestrepoInstituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.ORCID 0000-0002-4988-5220
Carolina López-MurilloInstituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.
Pablo Valderrama-CarmonaInstituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.
Natalia Orozco-SantaInstituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.ORCID 0000-0002-6911-9021
Johana GomezGrupo de Neurociencias de Antioquia, Facultad de Medicina, SIU, Universidad de Antioquia, Medellín, Colombia.
Johanna Gutiérrez-VargasInstituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.
Renato MoragaBiomedical Neuroscience Institute BNI, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0002-9412-3380
Jorge ToledoBiomedical Neuroscience Institute BNI, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0001-8678-558X
Jessica Lisa LittauMolecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0003-4609-1828
Steffen HärtelBiomedical Neuroscience Institute BNI, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0002-8913-1757
Joseph F Arboleda-VelásquezSchepens Eye Research Institute of Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
Diego Sepulveda-FallaMolecular Neuropathology of Alzheimer's Disease, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0003-0176-2042
Francisco LoperaGrupo de Neurociencias de Antioquia, Facultad de Medicina, SIU, Universidad de Antioquia, Medellín, Colombia.ORCID 0000-0002-5238-0231
Gloria Patricia Cardona-GómezÁrea de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.ORCID 0000-0002-3814-4494
Andrés VillegasGrupo de Neurociencias de Antioquia, Facultad de Medicina, SIU, Universidad de Antioquia, Medellín, Colombia.ORCID 0000-0003-1971-4364
Rafael Posada-DuqueInstituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Medellín, Colombia.ORCID 0000-0002-4492-3400
Universidad de Antioquia · COInstituto de Neurociencia Biomédica · CLUniversität Hamburg · DEMassachusetts Eye and Ear Infirmary · US

Funding

Charting vascular contributions to white matter disease in familial Alzheimer's disease and CADASILRF1NS110048 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH, SEPULVEDA-FALLA, DIEGO · 2018 to 2019
$3.6M
NINDS NIH HHS RF1 NS110048
6 · The paper itself

Abstract

In response to brain insults, astrocytes become reactive, promoting protection and tissue repair. However, astroglial reactivity is typical of brain pathologies, including Alzheimer's disease (AD). Considering the heterogeneity of the reactive response, the role of astrocytes in the course of different forms of AD has been underestimated. Colombia has the largest human group known to have familial AD (FAD). This group carries the autosomal dominant and fully penetrant mutation E280A in PSEN1, which causes early-onset AD. Recently, our group identified an E280A carrier who did not develop FAD. The individual was homozygous for the Christchurch mutation R136S in APOE3 (APOEch). Remarkably, APOE is the main genetic risk factor for developing sporadic AD (SAD) and most of cerebral ApoE is produced by astroglia. Here, we characterized astrocyte properties related to reactivity, glutamate homeostasis, and structural integrity of the gliovascular unit (GVU), as factors that could underlie the pathogenesis or protection of AD. Specifically, through histological and 3D microscopy analyses of postmortem samples, we briefly describe the histopathology and cytoarchitecture of the frontal cortex of SAD, FAD, and APOEch, and demonstrate that, while astrodegeneration and vascular deterioration are prominent in SAD, FAD is characterized by hyperreactive-like glia, and APOEch displays the mildest astrocytic and vascular alterations despite having the highest burden of Aβ. Notably, astroglial, gliovascular, and vascular disturbances, as well as brain cell death, correlate with the specific astrocytic phenotypes identified in each condition. This study provides new insights into the potential relevance of the gliovasculature in the development and protection of AD. To our knowledge, this is the first study assessing the components of the GVU in human samples of SAD, FAD, and APOEch.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E3BrainHomozygoteHumansMutationAmyloid beta-PeptidesApolipoprotein E3APOEchastrocytesfamilial Alzheimer's diseasegliovascular unitmicrogliasporadic Alzheimer's disease

Identifiers

PMID36130084
PMCPMC10041169
OpenAlexW4296709224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.